Atopic Dermatitis Treated Safely with Dupilumab during Pregnancy: A Case Report and Review of the Literature

Abstract Dupilumab is currently the only biologic treatment approved for moderate-to-severe atopic dermatitis. Though limited, available clinical data describing dupilumab use in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal ou...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Case reports in dermatology Ročník 13; číslo 2; s. 248 - 256
Hlavní autoři: Lobo, Yolanka, Lee, Ruby C., Spelman, Lynda
Médium: Journal Article
Jazyk:angličtina
Vydáno: Basel, Switzerland S. Karger AG 01.05.2021
Karger Publishers
Témata:
Antibodies
atopic dermatitis
Birth defects
Breastfeeding & lactation
Case and Review
Case reports
Dermatitis
Drug dosages
dupilumab
Eczema
Fetuses
Gastroenterology
Immunoglobulins
Inflammatory bowel disease
Light therapy
Miscarriage
Monoclonal antibodies
Patients
Pregnancy
Quality of life
Steroids
Womens health
Pregnancy
Atopic dermatitis
Dupilumab
ISSN:1662-6567, 1662-6567
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Abstract Dupilumab is currently the only biologic treatment approved for moderate-to-severe atopic dermatitis. Though limited, available clinical data describing dupilumab use in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Systemic treatment in pregnant women with atopic dermatitis is currently restricted to corticosteroids, cyclosporine A, and azathioprine. Atopic dermatitis often has a deleterious course in pregnancy which can cause substantial distress and significantly impact on global health and quality of life. We report a case of severe atopic dermatitis treated safely with dupilumab during pregnancy with no adverse maternal or fetal outcomes observed. Our case highlights that dupilumab use in pregnancy has its place but should always be preceded by careful assessment of the risks and benefits. Clinicians are encouraged to enroll their patients in relevant pregnancy registry studies to monitor outcomes in women exposed to dupilumab during pregnancy and lactation.
Bibliografie:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-4
ObjectType-Report-1
ObjectType-Article-3
content type line 23
ISSN:1662-6567
1662-6567
DOI:10.1159/000515246